

Hyaluronates Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please use Medicare Request Form

Please indicate: Start	ease indicate: Start of treatment: Start date/ Continuation of therapy (Request Additional Series Below)						
Precertification Requested	Ву:		Phone:		Fax	c:	
A. PATIENT INFORMATION		_					
First Name:		Las	st Name:				
Address:		City	y:	Sta	te:	ZIP:	
Home Phone:	Work	R Phone:		Cell Phone:			
DOB:	Allergies:			Email:			
Current Weight:	lbs orkgs	Height:	inches or	cms			
B. INSURANCE INFORMATIO	N_	<u></u> _					
Aetna Member ID #: Does patient have other			er coverage?	coverage?			
Group #:			-	Carrier Name:			
Insured:		Insured:					
Medicare: Yes No If	yes, provide ID #:	Me	dicaid: Yes	No If yes, pro	vide ID #:		
C. PRESCRIBER INFORMATION							
First Name:		Last Name:		(Check One)): M.D.	D.O. N.P. P.A.	
Address:			City:	Sta	ite:	ZIP:	
Phone:	Fax:	St Lic #:	NPI#:	DEA #:	U	JPIN:	
Provider Email:		Office Contact Name:			Phone:		
Specialty (Check one): O)rthonedic ☐ Primary !	 Provider					
D. DISPENSING PROVIDER/A							
Place of Administration:		MIGN	Dispensing Provi	ider/Pharmacy:	Patient S	Selected choice	
☐ Self-administered		Dispensing Provider/Pharmacy: Patient Selected choice ☐ Physician's Office ☐ Retail Pharmacy					
Outpatient Infusion Center			☐ Specialty Pharmacy ☐ Other				
Center Name:			Name:				
Home Infusion Center Phone:			Address:				
Administration code(s) (CF		Phone:	Phone: Fax:				
Address:			TIN:		PIN:		
E. PRODUCT INFORMATION							
Request is for:	•	☐ Hymovis (high	•		-	(hylan G-F 20)	
	☐ Durolane (hyaluronic acid)☐ Gel-One (cross-linked hyaluronate)☐ Monovisc (high molecular weight hyaluronan				☐ Synvisc-One (hylan G-F 20) ☐ Triluron (sodium hyaluronate)		
	(cross-linked hyaluronate) 3 (sodium hyaluronate 0.84%		h molecular weight hya			(sodium hyaluronate)	
	850 (sodium hyaluronate)	☐ Supartz FX (so	odium hyaluronate)		`	(sodium hyaluronate)	
☐ Hyalgan	(sodium hyaluronate)	Synojoynt (1%	sodium hyaluronate)			ium hyaluronate	
Dose:		Freq	luency:				
F. DIAGNOSIS INFORMATION	I – Please indicate primary	ICD Code and specify an	y other where applicab	ole.			
Primary ICD Code:	Secor	ndary ICD Code:		Other ICD C	ode:		
G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.							
For All Requests (clinical documentation required for all requests):							
Yes No Has the patient been diagnosed with osteoarthritis (OA) of the knee?							
Yes No Is the diagnosis supported by radiographic evidence of osteoarthritis of the knee, such as joint space narrowing, subchondral sclerosis, osteophytes, and sub-chondral cysts?							
Yes No At the time of diagnosis, did/does the patient have at least 5 of the following signs and symptoms?							
Select all that apply: Bony enlargement							
☐ Bony tenderness ☐ Crepitus (noisy, grating sound) on active motion							
☐ Erythrocyte sedimentation rate (ESR) less than 40 mm per hour							
☐ Less than 30 minutes of morning stiffness							
☐ No palpable warmth of synovium							
☐ Over 50 years of age ☐ Rheumatoid factor less than 1:40 titer (agglutination method)							
☐ Synovial fluid signs (clear fluid of normal viscosity and WBC less than 2000/mm3)							
Yes No Does the patient have knee pain that interferes with functional activities (e.g., ambulation or prolonged standing)?							



Hyaluronates Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB				
G. CLINICAL INFORMATION (continued) - F	Required clinical information must be comp	eted in its <u>entirety</u> for all precertif	cation requests.				
Yes No Has the patient experienced an inadequate response or adverse effects with non-pharmacologic treatment options (e.g., physical therapy, regular exercise, insoles, knee bracing, weight reduction)?							
Yes No Has the patient experienced an inadequate response or intolerance to a trial of an analgesic (e.g., acetaminophen up to 3 to 4 grams per day, non-steroidal anti-inflammatory drugs [NSAIDs], topical capsaicin cream) for at least 3 months?							
└────────────────────────────────────							
Yes No Has the patient experienced an inadequate response or intolerance to a trial of intraarticular steroid injections for at least 3 months?							
Yes No Does the patient have a contraindication to a trial of intraarticular steroid injections for at least 3 months?							
Yes No Is the patient scheduled to undergo a total knee replacement within 6 months of starting treatment?							
Yes No Is this request for Orthovisc, Monovisc or Synvisc One?							
☐ Yes ☐ No Has the patient received Orthovisc in the past? ☐ Yes ☐ No Does the patient have a documented contraindication to Orthovisc?							
Yes No Does the patient have a documented contraindication to Orthovisc?							
☐ Yes ☐ No Does the patient have a documented contraindication to Orthovisc?							
☐ Yes ☐ No Has the patient received Monovisc in the past?							
☐ Yes ☐ No Does the patient have a documented contraindication to Monovisc?							
Yes No Does the patient have a documented intolerance to Monovisc?							
☐ Yes ☐ No Does the patient have a documented contraindication to Monovisc?							
☐ Yes ☐ No Has the patient received Synvisc One in the past? ☐ Yes ☐ No Does the patient have a documented contraindication to Synvisc One?							
Yes No Does the patient have a documented contraindication to Synvisc One?							
Yes No Does the patient have a documented intolerance to dynvise one?							
For continuation of a current series (clinical documentation required):							
☐ Yes ☐ No Is the patient in the middle of therapy with the requested product?							
Please indicate dates(s) of previous injection(s):/ / // / /							
)	· · · · · · · · · · · · · · · · · · ·						
For continuation as re-start of a new series (clinical documentation required):							
What product did the patient last receive?							
Enter date of last injection from prior series://							
Yes No Was the previous series of injections completed at least 6 months prior to this request?							
☐ Yes ☐ No Has the patient experienced improvement in pain and functional capacity following previous injections?							
H. ACKNOWLEDGEMENT							
Request Completed By (Signature Require	red):		Date: / /				
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent							
insurance act, which is a crime and subjects such person to criminal and civil penalties.							

The plan may request additional information or clarification, if needed, to evaluate requests.